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Abstract
The association between obesity and colorectal neoplasia may be mediated by inflammation.
Circulating levels of C-reactive protein (CRP), interleukin-6 (IL-6), and tumor necrosis factor-α
(TNF-α) are elevated in the obese. Adipose tissue can produce and release the inflammatory cytokines
that are potentially procarcinogenic. We examined circulating levels of CRP, IL-6, and TNF-α in
relation to risk factors and the prevalence of colorectal adenomas. Plasma levels of CRP, IL-6, and
TNF-α were quantified in 873 participants (242 colorectal adenoma cases and 631 controls) in a
colonoscopy-based cross-sectional study conducted between 1998 and 2002. Multivariable logistic
regression was used to estimate associations between levels of inflammatory cytokines, colorectal
adenomas, and known risk factors. Several known risk factors for colorectal neoplasia were
associated with higher levels of inflammatory cytokines such as older age, current smoking, and
increasing adiposity. The prevalence of colorectal adenomas was associated with higher
concentrations of IL-6 and TNF-α, and to a lesser degree, with CRP. For IL-6, adjusted odds ratios
for colorectal adenomas were 1.78 (95% confidence interval [CI]: 1.18–2.68) for the second highest
plasma level, and 1.84 (95% CI: 1.24– 2.74) for the highest level compared with the reference level.
A similar association was found with TNF-α, with adjusted odds ratios of 1.54 (95% CI: 1.02–2.33)
and 1.65 (95% CI: 1.09–2.50), respectively. Our findings indicate that inflammation might be
involved in the early development of colorectal neoplasia, and suggest that systemic inflammatory
cytokines might be an indicator of obesity and other risk factors for colorectal neoplasia.
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Introduction
Previous studies have shown that obesity is positively associated with colorectal adenomas
and cancer 1. Possible mechanisms for the positive association between obesity and colorectal
neoplasia include the obesity-induced insulin-related pathway 1, and inflammation 2,3.
Adipose tissue is now recognized as an endocrine organ rather than a simple fat storage site,
and a wide range of inflammatory cytokines are released from adipose tissue, including tumor
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necrosis factor-α (TNF-α) and interleukin-6 (IL-6) 4,5. Circulating levels of C-reactive protein
(CRP), TNF-α, and IL-6 are elevated in the obese 6, and decrease after weight loss among the
same subjects 7,8. Based on growing evidence suggesting procarcinogenic effects of the
proinflammatory cytokines 9–11, we hypothesized that systemic inflammation might mediate
the association between obesity and colorectal neoplasia. The aims of the present study were
(1) to examine associations of levels of CRP, IL-6 and TNF-α and colorectal cancer risk factors
(older age, high BMI, and smoking) and protective factors (high physical activity and use of
NSAIDs), and (2) to determine whether circulating levels of CRP, IL-6 and TNF-α were
positively associated with prevalent colorectal adenomas.
Materials and Methods
Study population
Study participants were drawn from consecutive patients who underwent colonoscopy at the
UNC Hospitals (Chapel Hill, NC) for a variety of indications including abdominal pain,
bleeding, and, or screening between August 1, 1998 and March 4, 2000 (Diet and Health Study
(DHS) III), and for screening between November 5, 2001 and December 20, 2002 (DHS IV),
respectively. Patients were eligible to participate in the study if they were 30 years of age or
older, could provide informed consent and complete a telephone interview, and had no known
history of polyposis (>100 polyps), colon resection, colorectal cancer, colitis, or colorectal
adenomas. Patients were excluded if they had inadequate preparation, or incomplete
colonoscopic examinations (cecum not reached). At the time of colonoscopy all elevated
lesions were biopsied or removed. Biopsy specimens were placed in formalin and submitted
directly to pathology for sectioning and staining. A single experienced study pathologist
(J.T.W) examined all pathologic specimens and used a standardized form to record the total
number of polyps and the maximum diameter (in millimeters), location, histologic type and
atypia grade of each polyp. Any polyp with tubular, tubulovillous or villous pathology, or that
had mixed adenomatous and hyperplastic characteristics, was classified as an adenoma.
Data collection
DHS research staff weighed all subjects and measured their height, waist and hip
circumferences prior to colonoscopy. Information about demographic characteristics,
education, medical history, NSAID use, smoking and other lifestyle exposures was collected
by telephone interview within 12 weeks of the colonoscopy using a structured questionnaire.
Dietary intake was assessed using the Block food frequency questionnaire (DHS III) 12 and
the NCI quantitative food frequency questionnaire (DHS IV) 13. Physical activity was
estimated by computing weekly energy expenditure in METs (Metabolic Equivalents – a
standard measure of activity) based on the duration and intensity of various occupational and
non-occupational activities during typical days in the previous year. This study was approved
by the institutional review board at the University of North Carolina School of Medicine.
Samples for analyses
There were 2,162 patients (926 for the DHS III and 1,236 for the DHS IV) who met the
eligibility criteria described above. Overall, 84.3% of the eligible patients (N = 1,822) were
asked to participate in the study; of these, 89.6% (N = 1,633) agreed. Telephone interviews
were completed with 75.5% of the subjects who consented to participate (N = 1,233). The final
study sample consisted of 873 participants (327 for the DHS III and 546 for the DHS IV) with
plasma samples for cytokine assays. There were slightly more men in the final study sample
(45% vs. 40%, p < 0.04), compared with those who were interviewed but not included in
cytokine assays. However, there were no significant differences in other demographic
characteristics such as age and race.
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Specimen collection and handling conditions were similar for DHS III and IV. Fasting blood
samples were collected from participants at the time of colonoscopy. Plasma was extracted
from blood samples and stored in aliquots at −80°C until analyses. Plasma concentrations of
inflammatory cytokines were quantified using commercially available ultrasensitive ELISA
kits for human CRP (Biosource, Carlsbad, CA), and human IL-6 and TNF-α (Diagnostic
System Laboratories Inc., Webster, TX). Minimum detection levels were 1.6 ng/ml for CRP,
0.104 pg/ml for IL-6, and 0.09 pg/ml for TNF-α, according to the manufacturers. All assays
were run in duplicate, and levels were classified according to the average of each pair of
measurements. The intra- and inter-assay coefficients of variation were 2.8% and 0.19% for
CRP at 100 ng/ml; 11.3% and 16.9% for IL-6 at 0.16 pg/ml; and 5% and 11.2% for TNF-α at
1 pg/ml, respectively.
Statistical analysis
Selected characteristics were compared between cases and controls, and chi-square tests were
used to assess differences in proportions. Median and interquartile ranges for each
inflammatory cytokine were calculated according to case/control status. Mann-Whitney U test
p-values were calculated to evaluate the difference in circulating levels of each inflammatory
cytokine by case/control status because levels of inflammatory cytokines were not normally
distributed on raw or log-transformed scales. Spearman’s rank test was used for correlations
between circulating levels of three inflammatory cytokines.
Logistic regression was used to evaluate associations between risk factors for colorectal
neoplasia and high levels of inflammatory cytokines (CRP, IL-6 and TNF-α, dichotomized as
described below), after adjustment for age (30–49, 50–64, ≥65 years) and sex. Subjects were
classified as having high CRP or TNF-α if their measured levels were greater than or equal to
the value of the 66th percentile in the distribution of each cytokine among controls. For IL-6,
630 subjects (50% of cases and 65% of controls) had values below the detection limit; therefore,
we classified subjects as having high IL-6 if their levels were greater than or equal to the median
value among controls with detectable values (0.3571 pg/ml).
Risk factors for colorectal neoplasia that were evaluated for associations with inflammatory
cytokines were age at colonoscopy (30–49, 50–64, ≥65 years), sex, regular use of NSAIDs
(use ≥ 3 times per week during the past 5 years), smoking status (current, former, or never),
physical activity (average levels in the prior year categorized into tertiles based on the
distribution among controls), average daily total energy and fat intakes in the prior year (tertiles
based on distribution among controls), and obesity (measured by body mass index [BMI] alone
or BMI combined with waist circumference). BMI was categorized based on the World Health
organization (WHO) definitions 14 as obese (BMI ≥ 30 kg/m2), overweight (BMI 25–29 kg/
m2), and normal weight or underweight (BMI < 25 kg/m2). Waist circumference was
categorized according to the American Diabetes Association criteria for abdominal obesity as
action level 1 (men ≥ 94 cm, women ≥ 80 cm), action level 2 (men ≥102 cm, women, ≥ 88 cm)
or normal 15.
Odds ratios (ORs) and 95% confidence intervals for associations between colorectal adenomas
and each inflammatory cytokine were estimated using unconditional logistic regression
models. CRP and TNF-α were categorized based on tertile distributions among controls, with
the lowest tertile serving as the referent exposure category for each cytokine. For IL-6, subjects
with values below the detection limit in the assay were the referent exposure category, and the
remaining subjects were categorized into two groups using the median IL-6 level among
controls with detectable values (0.3571 pg/ml) as a cut point.
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Based on a directed acyclic graph (DAG) 16, age (30–49, 50–54, 55–59, 60–65, 65–69, 70–
74, ≥75 years), sex, smoking status, regular use of NSAIDs, comorbidity (defined as presence
of arthritis, diabetes, hypertension, or heart attack), study phase (DHS 3, or DHS 4), daily total
energy and fat intakes, physical activity and BMI were considered as potential confounding
factors. To determine which covariates should be entered in the final multivariate models, we
constructed a full model with all potential confounders, and assessed change in beta coefficients
for high levels of inflammatory cytokines versus the reference categories in relation to
occurrence of colorectal adenomas. Age and sex were included in all models, and other
covariates were retained if the beta coefficient for any cytokine changed by more than 10%
when they were removed. Final models for each inflammatory cytokine included age (30–49,
50–64, or ≥65), sex and obesity (assessed by BMI combined with waist circumference: BMI
<25; BMI 25–29.9 kg/m2 and action level 1 abdominal adiposity; BMI 25–29.9 kg/m2 and
action level 2 abdominal adiposity; BMI ≥ 30 kg/m2 and action level 1 abdominal adiposity;
or BMI ≥ 30 kg/m2 and action level 2 abdominal adiposity).
Levels of each inflammatory cytokine were compared between case subgroups defined
according to villous histology (villous or non-villous), the size of the largest adenoma (<10
mm or ≥ 10 mm in diameter), and the presence of multiple adenomas (1, or ≥ 2 adenomas).
Participants with more than one adenoma were classified based on the most advanced or largest
adenoma, respectively. Mann-Whitney U tests were used to assess median differences in
cytokine levels between case subtypes.
All statistical tests were two-sided. All analyses were performed using Stata version 9.0 (Texas
Station, TX).
Results
Selected characteristics of colorectal adenoma cases and controls are shown in Table 1. The
median age was 58 years in cases and 54 years in controls. Compared with controls, cases were
more likely to be male, and were less likely to have used NSAIDs regularly in the past 5 years.
Cases were also more likely to self-report comorbid conditions (arthritis, hypertension, heart
attack or diabetes.) Although associations did not reach statistical significance, cases were also
more likely to be current smokers, obese (based on both BMI and waist circumference), and
less physically active, and to have had higher total energy and fat intakes than controls.
The median level of TNF-α was 1.962 pg/ml (IQR: 1.419–2.277) in cases and 1.843 pg/ml
(IQR: 1.199–2.470) in controls (Mann-Whitney U test, p < 0.0034). For CRP, the median
concentration was 7,582.4 ng/ml (interquartile range: 2,376.9 – 16,823.3) in cases and 5,699.04
ng/ml (interquartile range: 2,066.3 – 15,646.4) in controls. The median difference in CRP levels
was not statistically significant (p = 0.2547). Median IL-6 levels were zero in both cases and
controls; however, the Mann-Whitney U test p-value was highly significant (p < 0.001),
indicating that the IL-6 concentration of a randomly selected case was higher than would be
expected by chance alone, compared with the IL-6 concentration of a randomly selected
control. The three cytokines were significantly, but only weakly correlated with one another;
the Spearman’s (Rho) correlation coefficients were 0.3431 between CRP and IL-6, 0.3239
between IL-6 and TNF-α, and 0.2028 between CRP and TNF-α (all p-values < 0.001).
Many known risk factors for colorectal neoplasia were positively associated with high levels
of CRP, IL-6 and TNF-α (Table 2). Older age, current smoking, and higher adiposity were
positively associated with prevalence of high levels of the inflammatory cytokines. When
considered in combination with action level 2 abdominal adiposity, BMI ≥ 30 (kg/m2) appeared
to be more strongly related to high levels of inflammatory cytokines than when considered
alone, particularly for CRP (OR = 5.36, 95% CI: 3.61–7.96 for BMI ≥ 30 [kg/m2], and OR =
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6.26, 95% CI: 4.04–9.68 for BMI ≥ 30 [kg/m2] and action level 2 abdominal adiposity). This
association did not vary between men and women (p for interaction between obesity and sex
in relation to high levels of CRP = 0.8115).
Subjects in the highest tertiles of total energy and fat intakes were more likely to have high
CRP than those in the lowest tertiles of intakes. Subjects in the highest tertile of fat intake were
also more likely to have high IL-6 and TNF-α than those in the lowest tertile of fat intake.
Prevalence of high CRP and TNF-α was inversely associated with physical activity above the
reference level. Although regular use of NSAIDs is a generally-accepted protective factor for
colorectal neoplasia, regular users of NSAIDs in this study had a slightly increased prevalence
of high levels of inflammatory cytokines relative to non-regular users. Finally, women were
more likely to have high CRP than men, although there was no association between sex and
IL-6 or TNF-α.
Table 3 shows crude and adjusted odds ratios and 95% confidence intervals for associations
between colorectal adenomas and plasma levels of inflammatory cytokines. Overall, the
prevalence of colorectal adenomas was positively associated with IL-6 and TNF-α above
reference levels. Specifically, for IL-6, adjusted odds ratios for colorectal adenomas were 1.78
(95% CI: 1.18–2.68) for the second highest category, and 1.84 (95% CI: 1.24–2.74) for the
highest category compared with the reference category. A similar association was found with
TNF-α, for which adjusted odds ratios for the second and third highest levels were 1.54 (95%
CI: 1.02–2.33) and 1.65 (95% CI: 1.09–2.50), respectively. The prevalence of colorectal
adenomas was also slightly increased in association with the highest category of circulating
CRP only (adjusted OR = 1.45, 95% CI: 0.95–2.23).
To evaluate whether higher levels of circulating inflammatory cytokines were associated with
advanced pathological features of colorectal adenomas, we performed separate analyses
comparing adenoma subtypes. Out of 242 adenoma cases, 22 (9%) had adenomas with villous
histology, 56 (23%) had adenomas ≥10 mm in diameter, and 48 (20%) had more than 1
adenoma. The median CRP level was 11,480.34 ng/ml (IQR: 5,760.25, 25,263.24) for adenoma
with villous histology, and 7,050.6 ng/ml (IQR: 2,302.28, 16,504.8) for adenomas with no
villous component (Mann-Whitney U test, p < 0.0391). There was no significant difference in
median concentrations of IL-6 and TNF-α according to villous histology. In addition, levels
of inflammatory cytokines were not associated with large adenomas or multiple adenomas.
Discussion
In this colonoscopy-based cross-sectional study of colorectal adenomas, circulating levels of
IL-6 and TNF-α, and to a lesser degree CRP, were positively associated with the prevalence
of colorectal adenomas. Several known risk factors for colorectal neoplasia also were
associated with high levels of inflammatory cytokines, specifically older age, current smoking,
increasing adiposity, physical inactivity, and higher caloric and fat intake.
Previous studies have not evaluated associations between cytokine levels and colorectal
adenomas, but several have evaluated associations with colorectal cancer, with mixed results.
Our findings for adenomas are in agreement with results for colorectal cancer from a nested
case-control study in the CLUEII cohort, in which Erlinger et al.18 found a positive association
with the highest quartile of CRP at baseline compared to the lowest quartile. Two prospective
studies based on a Japanese population 19 and a cohort of Finish male smokers 20 also support
an association between CRP and colorectal cancer, but there was no clear relationship between
CRP and colorectal cancer in the Women’s Health Study 21, or in the Japan Collaborative
Cohort Study 22. Few studies have evaluated plasma levels of IL-6 or TNF-α in relation to
colorectal neoplasia. Among older adults (aged 70–79 years) participating in the Health Aging
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and Body Composition study, IL-6 and TNF-α as well as CRP were positively associated with
incident cancers and cancer deaths 23. However, cancer site-specific estimates of associations
with each cytokine were not presented.
Accumulating evidence suggests that systemic inflammation might be a plausible mechanism
for colon carcinogenesis. Studies have shown that genetic variations in inflammation-related
genes such as IL-6, IL-8 and IL-10 are associated with susceptibility to colorectal cancer and
adenomas 3,9. IL-6 appears to stimulate cell growth, and inhibit apoptosis 2,11. TNF-α is a
key cytokine that is involved in the regulation of cytokines during inflammatory responses
10. Although TNF-α was first identified as a host-induced substance that is selectively toxic
to tumor cells at high doses 24, at physiologic levels TNF-α promotes cellular proliferation
and inhibits apoptosis, at least partly by inducing NF-κB 10. CRP upregulates the expression
of adhesion molecules, and increases the release of IL-1, IL-6, IL-18, and TNF-α from
mononuclear phagocytes 25.
With regard to associations between inflammatory cytokines and risk factors for colorectal
neoplasia, our findings are largely in agreement with previous studies. Obesity is a known risk
factor for colorectal neoplasia, and has recently been characterized as a state of low-grade
systemic inflammation 6. Circulating levels of inflammatory cytokines were elevated in obese
individuals compared with lean persons 26, and levels have been shown to decrease after weight
loss 7,27. It is now recognized that adipose tissue can synthesize and release cytokines such
as TNF-α and IL-6 28. Strong positive associations between obesity and levels of the
proinflammatory cytokines in our study were consistent with expectations given that adipose
tissue is a source of cytokines. CRP and IL-6 levels increase with chronological age 29,30, but
it remains unclear whether this occurs as a consequence of aging or is simply a reflection of
underlying health conditions that are more common with increasing age 31. Smoking also has
been associated with elevated levels of CRP and IL-6 32–34. Although the effect of smoking
on inflammatory cytokines appeared to persist for several years after smoking cessation in one
study 33, only current (not past) smoking was associated with high levels of inflammatory
cytokines in our study. In addition, high levels of physical activity have been associated with
decreased concentrations of CRP, IL-6 and TNF-α, independent of obesity 35.
Weak positive associations between regular use of NSAIDs and high levels of inflammatory
cytokines were contrary to our expectations. This could have been due to confounding by
indication because comorbidity was related both to regular use of NSAIDs and to high levels
of inflammatory cytokines. However, adjustment for comorbidity did not change the direction
of associations, although the strength of the associations was slightly attenuated. Alternatively,
inflammatory cytokines measured at the time of colonoscopy may not have reflected typical
levels among regular NSAID users, since it is recommended that patients abstain from NSAID
use for one week prior to colonoscopy. A positive association between NSAIDs and cytokines
might be evident if cytokine levels among regular users are elevated relative to non-users in
the absence of NSAID use. Finally, the protective effect of NSAIDs might not be exerted via
modifying circulating cytokines, as we hypothesized. There have been inconsistent findings;
while aspirin administration has been shown to reduce levels of CRP by 29% and IL-6 by 37%
in angina patients 36, Feldman et al. did not detect any significant change in serum CRP levels
with low dose aspirin use 37.
Our study has several strengths. First, colorectal adenomas were completely ascertained by
colonoscopy to the cecum, and were reviewed by a single experienced pathologist. Also,
detailed information on exposure history enabled the assessment of a wide range of potential
confounding factors as well as the evaluation of relations between inflammatory cytokines and
risk factors for colorectal neoplasia.
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The temporal ambiguity inherent in a cross-sectional study is a limitation, but it is unlikely that
adenomas themselves would cause a systemic increase in inflammatory cytokines. In our study,
the median size of the largest adenoma was only 5 millimeters, and macrophage infiltration,
which is uncommon in adenomas in general, is particularly rare in small adenomas 38. We
recognize that a one time measurement of circulating inflammatory cytokines may not
represent an individual’s inflammatory status during the development of adenomas, and that
measured levels may be influenced by diurnal or stress induced variation. For example, patients
in our study could have experienced a short-term increase in plasma levels of CRP, IL-6 and
TNF-α given that they were awaiting colonoscopy, which may be a stressful event. However,
stress-induced activation of cytokines 39 would have not differed by case/control status. In
addition, while there is a report that TNF-α is significantly lower in the morning than in the
evening 40, CRP 41 and IL-6 40 are tightly regulated over time, and are not affected by
circadian variation 40. Lastly, our finding that IL-6 levels were below the detection limit in
about 50% of cases and 65% of controls was consistent with expectations, since it has been
recognized that IL-6 is generally undetectable in healthy individuals without infection, trauma
or other inflammatory conditions 42.
We have shown associations between the prevalence of colorectal adenomas and increased
levels of IL-6 and TNF-α, and, to a lesser degree, CRP. These findings indicate that
inflammation might be involved in the early development of colorectal neoplasia, and suggest
that systemic inflammatory cytokines might be an indicator of obesity and other risk factors.
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Table 2










  50–64 1.39 (0.97–2.0) 1.6 (1.02–2.5) 1.16 (0.82–1.65)
  ≥ 65 1.62 (1.06–2.48) 2.17 (1.31–3.59) 1.94 (1.29–2.91)
Female sex 2.25 (1.67–3.04) 0.85 (0.61–1.19) 0.94 (0.71–1.25)
Regular use of NSAIDs 1.19 (0.88–1.62) 1.47 (1.03–2.12) 1.34 (1.0–1.81)
Smoking status
  Current 2.05 (1.31–3.23) 2.59 (1.6–4.2) 1.23 (0.79–1.91)
  Past 0.85 (0.61–1.2) 1.01 (0.67–1.51) 0.93 (0.67–1.29)
Obesity
  BMI 25 – 29.9 (kg/m2) 1.94 (1.34–2.83) 1.85 (1.22–2.83) 1.46 (1.04–2.05)
    Level 1 abdominal adiposity‡ 1.75 (1.1–2.79) 1.93 (1.17–3.18) 1.44 (0.95–2.2)
    Level 2 abdominal adiposity‡ 2.1 (1.33–3.23) 1.71 (0.83–3.55) 1.46 (0.96–2.22)
  BMI ≥ 30 (kg/m2) 5.36 (3.61–7.96) 2.47 (1.58–3.85) 1.91 (1.32–2.76)
    Level 1 abdominal adiposity‡ 3.54 (1.9–6.6) 1.74 (1.04–2.92) 1.63 (0.89–2.97)
    Level 2 abdominal adiposity‡ 6.26 (4.04–9.68) 2.81 (1.73–4.56) 2.03 (1.35–3.05)
Physical activity (MET-minutes/day)
  2nd tertile* 0.74 (0.5–1.09) 0.71 (0.44–1.14) 0.69 (0.47–1.01)
  3rd tertile* 0.65 (0.43–0.99) 1.09 (0.68–1.74) 0.73 (0.49–1.09)
Daily energy intake (kcal)
  2nd tertile* 1.06 (0.72–1.56) 0.73 (0.45–1.17) 0.80 (0.55–1.16)
  3rd tertile* 1.45 (0.97–2.16) 1.16 (0.74–1.81) 1.02 (0.7–1.49)
Total daily fat intake (g)
  2nd tertile* 1.01 (0.68–1.5) 0.92 (0.57–1.48) 0.86 (0.58–1.25)
  3rd tertile* 1.48 (1.0–2.19) 1.29 (0.82–2.04) 1.24 (0.85–1.81)
†
Adjusted for age (30–49, 50–64, ≥65 years) and sex
‡
Defined based on waist circumference. In women, <80 (cm) defined as normal, 80–87.9 as action level 1, and ≥ 88 as action level 2 abdominal obesity.
In men, <94 defined as normal, 94–101.9 as action level 1, and ≥102 as action level 2 abdominal obesity.
*
Tertiles are based on the distribution among controls.
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